Video

Mindy Mintz Mordecai on the Association Between Acid Reflux and Esophageal Cancer

Mindy Mintz Mordecai, founder, president, and CEO of the Esophageal Cancer Action Network (ECAN), discusses the link between acid reflux and esophageal cancer.

Mindy Mintz Mordecai, founder, president, and CEO of the Esophageal Cancer Action Network (ECAN), discusses the link between acid reflux and esophageal cancer.

ECAN has been working to not only spread awareness of the risk of esophageal cancer posed by reflux, but also spread awareness of the fact that reflux is not just heartburn. Mordecai explains that while esophageal cancer is the fastest increasing cancer among American men, a public opinion poll conducted by ECAN showed only 14% of Americans know that reflux can cause cancer.

Part of ECAN’s efforts include filing a petition with the FDA urging it to change the label on over-the-counter reflux medication to state that anyone who takes the medication may be at risk for esophageal cancer, and further, taking medication does not eliminate the risk of developing cancer.

Related Videos
Dr. Michael Bogenschutz
Photo credit: Max Mumby/Indigo via Getty Images
Dr. Maxwell Lloyd, a Clinical Fellow in Medicine, in the Department of Medicine, at Beth Israel Deaconess Medical Center in Boston.
Dr. Stephanie Alice Baker
Dr. Aditya Bardia is a professor in the Department of Medicine, Division of Hematology/Oncology, director of Translational Research Integration, and a member Signal Transduction and Therapeutics, at University of California, Los Angeles (UCLA) Health Jonsson Comprehensive Cancer Center.
Dr. Laura Dawson, a professor and chair of the department of Radiation Oncology at the University of Toronto, and a practicing radiation oncologist in the Radiation Medicine Program at Princess Margaret Cancer Center, University Health Network in Toronto.
Dr. Sattva S. Neelapu, a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Dr. Michael Bogenschutz, director of the NYU Langone Center for Psychedelic Medicine in New York,
Dr. Richard “Rick" Winneker